Ligand Pharmaceuticals Incorpor (LGND) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $223.91. BUY gates pass at $248.24, but concentration risk — Supplier: Hovione and concentration risk — Product: Captisol material sales argue for a more patient entry. Engine's entry $223.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate diversified royalty streams from high-value medicines. Revenue comes from royalties on partner-commercialized products (led by Kyprolis, Qarziba, Filspari),... Read more
Wait for pullback to $223.91. BUY gates pass at $248.24, but concentration risk — Supplier: Hovione and concentration risk — Product: Captisol material sales argue for a more patient entry. Engine's entry $223.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 7.7/10, growth 8.0/10). Score 6.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Ligand Pharmaceuticals Incorpor
Latest news
- NEWS RBC Capital raises Ligand Pharma stock price target on XOMA deal By Investing.com - Investing.com India — Investing.com India positive
- NEWS Ligand to Participate in June Investor Conferences - marketscreener.com — marketscreener.com neutral
- NEWS Ligand to Participate in June Investor Conferences - Yahoo Finance — Yahoo Finance neutral
- NEWS Ligand to Participate in June Investor Conferences - finance.yahoo.com — finance.yahoo.com positive
- NEWS Ligand Pharmaceuticals Bets Big on Royalty Growth - TipRanks — TipRanks positive
Generated 2026-06-15T12:26:44Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierHovione10-K Item 1A: 'We obtain Captisol from Hovione, our third-party manufacturer, primarily at their facilities in Ireland and Portugal.'
- HIGHProductCaptisol material sales10-K Item 1A: 'Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent approximately half of our royalty revenues.'
Material Events(8-K, last 90d)
- 2026-04-30Item 1.02MEDIUMLigand terminated the TR-Beta Program under its Master License Agreement with Viking Therapeutics effective May 4, 2026, citing Viking's material breach of its obligation to use Commercially Reasonable Efforts to develop and commercialize the program.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $223.91. BUY gates pass at $248.24, but concentration risk — Supplier: Hovione and concentration risk — Product: Captisol material sales argue for a more patient entry. Engine's entry $223.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.45, quality 7.7/10, growth 8.0/10). Target $252.05 (+1.5%), stop $209.51 (−18.5%), Setup A.R:R 2.0:1. Score 6.1/10, moderate confidence.
Take-profit target: $252.05 (+12.6% upside). Target $252.05 (+1.5%), stop $209.51 (−18.5%), Setup A.R:R 2.0:1. Stop-loss: $209.51.
Concentration risk — Supplier: Hovione; Concentration risk — Product: Captisol material sales; Analyst target reached - limited upside remaining.
Ligand Pharmaceuticals Incorpor trades at a P/E of 31.8 (forward 21.5). TrendMatrix value score: 4.5/10. Verdict: Buy (Wait for Entry).
14 analysts cover LGND with a consensus score of 4.3/5. Average price target: $278.
What does Ligand Pharmaceuticals Incorpor do?Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate...
Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and licenses technologies to generate diversified royalty streams from high-value medicines. Revenue comes from royalties on partner-commercialized products (led by Kyprolis, Qarziba, Filspari), Captisol material sales, and contract revenue; total royalty receipts were $176.9M in 2025. The Captisol platform underpins 17 FDA-approved products and is sole-sourced from Hovione.